Online Mendelian Inheritance in Man (OMIM) (original) (raw)

  1. Aerts, J. M., Groener, J. E., Kuiper, S., Donker-Kooperman, W. E., Strijland, A., Ottenhoff, R., van Roomen, C., Mirzaian, M., Wijburg, F. A., Linthorst, G. E., Vedder, A. C., Rombach, S. M., Cox-Brinkman, J., Somerharju, P., Boot, R. G., Hollak, C. E., Brady, R. O., Poorthuis, B. J.Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Nat. Acad. Sci. 105: 2812-2817, 2008. [PubMed: 18287059] [Full Text: https://doi.org/10.1073/pnas.0712309105\]
  2. Anderson, W.A case of 'angeio-keratoma'. Brit. J. Derm. 10: 113-117, 1898.
  3. Asano, N., Ishii, S., Kizu, H., Ikeda, K., Yasuda, K., Kato, A., Martin, O. R., Fan, J.-Q.In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Europ. J. Biochem. 267: 4179-4186, 2000. [PubMed: 10866822] [Full Text: https://doi.org/10.1046/j.1432-1327.2000.01457.x\]
  4. Auray-Blais, C., Cyr, D., Ntwari, A., West, M. L., Cox-Brinkman, J., Bichet, D. G., Germain, D. P., Laframboise, R., Melancon, S. B., Stockley, T., Clarke, J. T. R., Drouin, R.Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Molec. Genet. Metab. 93: 331-340, 2008. [PubMed: 18023222] [Full Text: https://doi.org/10.1016/j.ymgme.2007.10.001\]
  5. Bach, G., Rosenmann, E., Karni, A., Cohen, T.Pseudodeficiency of alpha-galactosidase A. Clin. Genet. 21: 59-64, 1982. [PubMed: 6279339]
  6. Balendran, S., Oliva, P., Sansen, S., Mechtler, T. P., Streubel, B., Cobos, P. N., Lukacs, Z., Kasper, D. C.Diagnostic strategy for females suspected of Fabry disease. Clin. Genet. 97: 655-660, 2020. [PubMed: 31860127] [Full Text: https://doi.org/10.1111/cge.13694\]
  7. Bannwart, F.Morbus Fabry: Licht- und Elektronenmikroskopischer Herzbefund 12 Jahre nach erfolgreicher Nierentransplantation. Schweiz. Med. Wschr. 112: 1742-1747, 1982. [PubMed: 6294821]
  8. Beaudet, A. L., Caskey, C. T.Detection of Fabry's disease heterozygotes by hair root analysis. Clin. Genet. 13: 251-258, 1978. [PubMed: 205381] [Full Text: https://doi.org/10.1111/j.1399-0004.1978.tb01178.x\]
  9. Bernstein, H. S., Bishop, D. F., Astrin, K. H., Kornreich, R., Eng, C. M., Sakuraba, H., Desnick, R. J.Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J. Clin. Invest. 83: 1390-1399, 1989. [PubMed: 2539398] [Full Text: https://doi.org/10.1172/JCI114027\]
  10. Bird, T. D., Lagunoff, D.Neurological manifestations of Fabry disease in female carriers. Ann. Neurol. 4: 537-540, 1978. [PubMed: 217299] [Full Text: https://doi.org/10.1002/ana.410040610\]
  11. Blanch, L. C., Meaney, C., Morris, C. P.A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene. Hum. Mutat. 8: 38-43, 1996. [PubMed: 8807334] [Full Text: https://doi.org/10.1002/(SICI)1098-1004(1996)8:1<38::AID-HUMU5>3.0.CO;2-L]
  12. Blom, D., Speijer, D., Linthorst, G. E., Donker-Koopman, W. G., Strijland, A., Aerts, J. M. F. G.Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. Am. J. Hum. Genet. 72: 23-31, 2003. [PubMed: 12471562] [Full Text: https://doi.org/10.1086/345309\]
  13. Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L., Laster, L.Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. New Eng. J. Med. 276: 1163-1167, 1967. [PubMed: 6023233] [Full Text: https://doi.org/10.1056/NEJM196705252762101\]
  14. Brady, R. O., Schiffmann, R.Clinical features of and recent advances in therapy for Fabry disease. JAMA 284: 2771-2775, 2000. Note: Erratum: JAMA 285: 169 only, 2001. [PubMed: 11105184] [Full Text: https://doi.org/10.1001/jama.284.21.2771\]
  15. Branton, M. H., Schiffmann, R., Sabnis, S. G., Murray, G. J., Quirk, J. M., Altarescu, G., Goldfarb, L., Brady, R. O., Balow, J. E., Austin, H. A., III, Kopp, J. B.Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 81: 122-138, 2002. [PubMed: 11889412] [Full Text: https://doi.org/10.1097/00005792-200203000-00003\]
  16. Broadbent, J. C., Edwards, W. D., Gordon, H., Hartzler, G. O., Krawisz, J. E.Fabry cardiomyopathy in the female confirmed by endomyocardial biopsy. Mayo Clin. Proc. 56: 623-628, 1981. [PubMed: 6268901]
  17. Brown, L. K., Miller, A., Bhuptani, A., Sloane, M. F., Zimmerman, M. I., Schilero, G., Eng, C. M., Desnick, R. J.Pulmonary involvement in Fabry disease. Am. J. Resp. Crit. Care Med. 155: 1004-1010, 1997. [PubMed: 9116979] [Full Text: https://doi.org/10.1164/ajrccm.155.3.9116979\]
  18. Cable, W. J. L., Dvorak, A. M., Osage, J. E., Kolodny, E. H.Fabry disease: significance of ultrastructural localization of lipid inclusions in dermal nerves. Neurology 32: 347-353, 1982. [PubMed: 6278363] [Full Text: https://doi.org/10.1212/wnl.32.4.347\]
  19. Cable, W. J. L., Kolodny, E. H., Adams, R. D.Fabry disease: impaired autonomic function. Neurology 32: 498-502, 1982. [PubMed: 6803189] [Full Text: https://doi.org/10.1212/wnl.32.5.498\]
  20. Cable, W. J. L., McCluer, R. H., Kolodny, E. H., Ullman, M. D.Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment. Neurology 32: 1139-1145, 1982. [PubMed: 6289188] [Full Text: https://doi.org/10.1212/wnl.32.10.1139\]
  21. Clarke, J. T., Knaack, J., Crawhall, J. C., Wolfe, L. S.Ceramide trihexosidosis (Fabry's disease) without skin lesions. New Eng. J. Med. 284: 233-235, 1971. [PubMed: 5539345] [Full Text: https://doi.org/10.1056/NEJM197102042840503\]
  22. Clarke, J. T. R.Narrative review: Fabry disease. Ann. Intern. Med. 146: 425-433, 2007. [PubMed: 17371887] [Full Text: https://doi.org/10.7326/0003-4819-146-6-200703200-00007\]
  23. Clement, M., McGonigle, R. J. S., Monkhouse, P. M., Keogh, A. M., Marten, R. H., Bewick, M., Parsons, V.Renal transplantation in Anderson-Fabry disease. J. Roy. Soc. Med. 75: 557-560, 1982. [PubMed: 6283080] [Full Text: https://doi.org/10.1177/014107688207500716\]
  24. Colucci, W. S., Lorell, B. H., Schoen, F. J., Warhol, M. J., Grossman, W.Hypertrophic obstructive cardiomyopathy due to Fabry's disease. New Eng. J. Med. 307: 926-931, 1982. [PubMed: 6810178] [Full Text: https://doi.org/10.1056/NEJM198210073071505\]
  25. Crosbie, T. W., Packman, W., Packman, S.Psychological aspects of patients with Fabry disease. J. Inherit. Metab. Dis. 32: 745-753, 2009. [PubMed: 19924564] [Full Text: https://doi.org/10.1007/s10545-009-1254-1\]
  26. Davies, J. P., Winchester, B. G., Malcolm, S.Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum. Molec. Genet. 2: 1051-1053, 1993. [PubMed: 8395937] [Full Text: https://doi.org/10.1093/hmg/2.7.1051\]
  27. Efthimiou, J., McLelland, J., Betteridge, D. J.Short PR intervals and tachyarrhythmias in Fabry's disease. Postgrad. Med. J. 62: 285-287, 1986. [PubMed: 3086855] [Full Text: https://doi.org/10.1136/pgmj.62.726.285\]
  28. Elleder, M., Bradova, V., Smid, F., Budesinsky, M., Harzer, K., Kustermann-Kuhn, B., Ledvinova, J., Belohlavek, (NI), Kral, V., Dorazilova, V.Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease: report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch. A Pathol. Anat. Histopathol. 417: 449-455, 1990. [PubMed: 2173254] [Full Text: https://doi.org/10.1007/BF01606034\]
  29. Elleder, M., Christomanou, H., Kustermann-Kuhn, B., Harzer, K.Leptomeningeal lipid storage patterns in Fabry disease. Acta Neuropath. 88: 579-582, 1994. [PubMed: 7879606] [Full Text: https://doi.org/10.1007/BF00296496\]
  30. Eng, C. M., Banikazemi, M., Gordon, R. E., Goldman, M., Phelps, R., Kim, L., Gass, A., Winston, J., Dikman, S., Fallon, J. T., Brodie, S., Stacy, C. B., Mehta, D., Parsons, R., Norton, K., O'Callaghan, M., Desnick, R. J.A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68: 711-722, 2001. [PubMed: 11179018] [Full Text: https://doi.org/10.1086/318809\]
  31. Eng, C. M., Desnick, R. J.Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum. Mutat. 3: 103-111, 1994. [PubMed: 7911050] [Full Text: https://doi.org/10.1002/humu.1380030204\]
  32. Eng, C. M., Germain, D. P., Banikazemi, M., Warnock, D. G., Wanner, C., Hopkin, R. J., Bultas, J., Lee, P., Sims, K., Brodie, S. E., Pastores, G. M., Strotmann, J. M., Wilcox, W. R.Fabry disease: guidelines for the evaluation and management of the multi-organ system involvement. Genet. Med. 8: 539-548, 2006. [PubMed: 16980809] [Full Text: https://doi.org/10.1097/01.gim.0000237866.70357.c6\]
  33. Eng, C. M., Resnick-Silverman, L. A., Niehaus, D. J., Astrin, K. H., Desnick, R. J.Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am. J. Hum. Genet. 53: 1186-1197, 1993. [PubMed: 7504405]
  34. Fabry, J.Ein Beitrag Zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa hemorrhagica Hebrae). Arch. Derm. Syph. 43: 187-200, 1898.
  35. Faggiano, A., Pisani, A., Milone, F., Gaccione, M., Filippella, M., Santoro, A., Vallone, G., Tortora, F., Sabbatini, M., Spinelli, L., Lombardi, G., Cianciaruso, B., Colao, A.Endocrine dysfunction in patients with Fabry disease. J. Clin. Endocr. Metab. 91: 4319-4325, 2006. [PubMed: 16926253] [Full Text: https://doi.org/10.1210/jc.2006-0858\]
  36. Fan, J.-Q., Ishii, S., Asano, N., Suzuki, Y.Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nature Med. 5: 112-115, 1999. [PubMed: 9883849] [Full Text: https://doi.org/10.1038/4801\]
  37. Faraggiana, T., Churg, J., Grishman, E., Strauss, L., Prado, A., Bishop, D. F., Schuchman, E., Desnick, R. J.Light and electron-microscopic histochemistry of Fabry's disease. Am. J. Path. 103: 247-262, 1981. [PubMed: 6786101]
  38. Fellgiebel, A., Keller, I., Marin, D., Muller, M. J., Schermuly, I., Yakushev, I., Albrecht, J., Bellhauser, H., Kinateder, M., Beck, M., Stoeter, P.Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72: 63-68, 2009. [PubMed: 19122032] [Full Text: https://doi.org/10.1212/01.wnl.0000338566.54190.8a\]
  39. Flynn, D. M., Lake, B. D., Boothby, C. B., Young, E. P.Gut lesions in Fabry's disease without a rash. Arch. Dis. Child. 47: 26-33, 1972. [PubMed: 5018655] [Full Text: https://doi.org/10.1136/adc.47.251.26\]
  40. Franceschetti, A. T., Philippart, M., Franceschetti, A.A study of Fabry's disease. I. Clinical examination of a family with cornea verticillata. Dermatologica 138: 209-221, 1969. [PubMed: 5771636]
  41. Friedlaender, M. M., Kopolovic, J., Rubinger, D., Silver, J., Drukker, A., Ben-Gershon, Z., Durst, A. L., Popovtzer, M. M.Renal biopsy in Fabry's disease eight years after successful renal transplantation. Clin. Nephrol. 27: 206-211, 1987. [PubMed: 3107860]
  42. Friedman, L. S., Kirkham, S. E., Thistlethwaite, J. R., Platika, D., Kolodny, E. H., Schuffler, M. D.Jejunal diverticulosis with perforation as a complication of Fabry's disease. Gastroenterology 86: 558-563, 1984. [PubMed: 6420224]
  43. Frost, P., Tanaka, Y., Spaeth, G. L.Fabry's disease--glycolipid lipidoses. Histochemical and electron microscopic studies of two cases. Am. J. Med. 40: 618-627, 1966. [PubMed: 5948850] [Full Text: https://doi.org/10.1016/0002-9343(66)90123-9\]
  44. Germain, D., Biasotto, M., Tosi, M., Meo, T., Kahn, A., Poenaru, L.Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease. Hum. Genet. 98: 719-726, 1996. [PubMed: 8931708] [Full Text: https://doi.org/10.1007/s004390050292\]
  45. Germain, D. P., Avan, P., Chassaing, A., Bonfils, P.Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med. Genet. 3: 10, 2002. Note: Electronic Article. [PubMed: 12377100] [Full Text: https://doi.org/10.1186/1471-2350-3-10\]
  46. Germain, D. P., Benistan, K., Boutouyrie, P., Mutschler, C.Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. (Letter) Clin. Genet. 68: 93-95, 2005. [PubMed: 15952993] [Full Text: https://doi.org/10.1111/j.1399-0004.2005.00457.x\]
  47. Germain, D. P., Charrow, J., Desnick, R. J., Guffon, N., Kempf, J., Lachmann, R. H., Lemay, R., Linthorst, G. E., Packman, S., Scott, C. R., Waldek, S., Warnock, D. G., Weinreb, N. J., Wilcox, W. R.Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J. Med. Genet. 52: 353-358, 2015. [PubMed: 25795794] [Full Text: https://doi.org/10.1136/jmedgenet-2014-102797\]
  48. Germain, D. P., Poenaru, L.Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. Biochem. Biophys. Res. Commun. 257: 708-713, 1999. [PubMed: 10208848] [Full Text: https://doi.org/10.1006/bbrc.1999.0310\]
  49. Germain, D. P., Weidemann, F., Abiose, A., Patel, M. R., Cizmarik, M., Cole, J. A., Beitner-Johnson, D., Benistan, K., Cabrera, G., Charrow, J., Kantola, I., Linhart, A., Nicholls, K., Niemann, M., Scott, C. R., Sims, K., Waldek, S., Warnock, D. G., Strotmann, J.Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry. Genet. Med. 15: 958-965, 2013. [PubMed: 23703683] [Full Text: https://doi.org/10.1038/gim.2013.53\]
  50. Germain, D. P.Co-occurrence and contribution of Fabry disease and Klippel-Trenaunay-Weber syndrome to a patient with atypical skin lesions. Clin. Genet. 60: 63-67, 2001. [PubMed: 11531972] [Full Text: https://doi.org/10.1034/j.1399-0004.2001.600110.x\]
  51. Gruber, M.Cornea verticillata. (Eine einfach-dominante Variante der Hornhaut des menschlichen Auges). Ophthalmologica 111: 120-129, 1946. [PubMed: 20275792] [Full Text: https://doi.org/10.1159/000300313\]
  52. Gruber, M.Cornea verticillata. II. Mitteilung. Ophthalmologica 112: 88-91, 1946. [PubMed: 20275840] [Full Text: https://doi.org/10.1159/000300370\]
  53. Halsted, C. H., Rowe, J. W.Occurrence of celiac sprue in a patient with Fabry's disease. Ann. Intern. Med. 83: 524-525, 1975. [PubMed: 810052] [Full Text: https://doi.org/10.7326/0003-4819-83-4-524\]
  54. Hamburger, J., Dormont, J., De Montera, H., Hinglais, N.Sur une singuliere malformation familiale de l'epithelium renal. Schweiz. Med. Wschr. 94: 871-876, 1964. [PubMed: 14238342]
  55. Hamers, M. N., Wise, D., Ejiofor, A., Strijland, A., Robinson, D., Tager, J. M.Relationship between biochemical and clinical features in an English Anderson-Fabry family. Acta Med. Scand. 206: 5-10, 1979. [PubMed: 225929] [Full Text: https://doi.org/10.1111/j.0954-6820.1979.tb13460.x\]
  56. Hasholt, L., Sorensen, S. A., Wandall, A., Andersen, E. B., Arlien-Soborg, P.A Fabry's disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations. J. Med. Genet. 27: 303-306, 1990. [PubMed: 2161929] [Full Text: https://doi.org/10.1136/jmg.27.5.303\]
  57. Hasholt, L., Sorensen, S. A.Lysosomal alpha-galactosidase in endothelial cell cultures established from a Fabry hemizygous and normal umbilical veins. Hum. Genet. 72: 72-76, 1986. [PubMed: 3002954] [Full Text: https://doi.org/10.1007/BF00278821\]
  58. Heltianu, C., Costache, G., Azibi, K., Poenaru, L., Simionescu, M.Endothelial nitric oxide synthase gene polymorphisms in Fabry's disease. Clin. Genet. 61: 423-429, 2002. [PubMed: 12121349] [Full Text: https://doi.org/10.1034/j.1399-0004.2002.610605.x\]
  59. Hillsley, R. E., Hernandez, E., Steenbergen, C., Bashore, T. M., Harrison, J. K.Inherited restrictive cardiomyopathy in a 74-year-old woman: a case of Fabry's disease. Am. Heart J. 129: 199-202, 1995. [PubMed: 7817917] [Full Text: https://doi.org/10.1016/0002-8703(95)90062-4\]
  60. Hughes, D. A., Nicholls, K., Shankar, S. P., Sunder-Plassmann, G., Koeller, D., Nedd, K., Vockley, G., Hamazaki, T., Lachmann, R., Ohashi, T., Olivotto, I., Sakai, N., and 26 others.Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J. Med. Genet. 54: 288-296, 2017. Note: Erratum: J. Med. Genet. 55: 429 only, 2018. [PubMed: 27834756] [Full Text: https://doi.org/10.1136/jmedgenet-2016-104178\]
  61. Ioannou, Y. A., Zeidner, K. M., Gordon, R. E., Desnick, R. J.Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 68: 14-25, 2001. [PubMed: 11115376] [Full Text: https://doi.org/10.1086/316953\]
  62. Ishii, S., Kase, R., Okumiya, T., Sakuraba, H., Suzuki, Y.Aggregation of the inactive form of human alpha-galactosidase in the endoplasmic reticulum. Biochem. Biophys. Res. Commun. 220: 812-815, 1996. [PubMed: 8607847] [Full Text: https://doi.org/10.1006/bbrc.1996.0486\]
  63. Johnston, A. W., Frost, P., Spaeth, G. L., Renwick, J. H.Linkage relationships of the angiokeratoma (Fabry) locus. Ann. Hum. Genet. 32: 369-374, 1969. [PubMed: 5307232] [Full Text: https://doi.org/10.1111/j.1469-1809.1969.tb00088.x\]
  64. Johnston, A. W., Sanger, R.Linkage relationship of the loci for Anderson-Fabry disease and the Xg blood groups. Ann. Hum. Genet. 45: 155-157, 1981. [PubMed: 6274251] [Full Text: https://doi.org/10.1111/j.1469-1809.1981.tb00317.x\]
  65. Johnston, A. W.Fabry's disease without skin lesions. (Letter) Lancet 289: 1277 only, 1967. Note: Originally Volume 1.
  66. Jung, S.-C., Han, I. P., Limaye, A., Xu, R., Gelderman, M. P., Zerfas, P., Tirumalai, K., Murray, G. J., During, M. J., Brady, R. O., Qasba, P.Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc. Nat. Acad. Sci. 98: 2676-2681, 2001. [PubMed: 11226298] [Full Text: https://doi.org/10.1073/pnas.051634498\]
  67. Kaneski, C. R., Moore, D. F., Ries, M., Zirzow, G. C., Schiffmann, R.Myeloperoxidase predicts risk of vasculopathic events in hemizygous males with Fabry disease. Neurology 67: 2045-2047, 2006. [PubMed: 17159117] [Full Text: https://doi.org/10.1212/01.wnl.0000247278.88077.09\]
  68. Kim, W., Pyeritz, R. E., Bernhardt, B. A., Casey, M., Litt, H. I.Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy. Am. J. Med. Genet. 143A: 377-381, 2007. [PubMed: 17256799] [Full Text: https://doi.org/10.1002/ajmg.a.31600\]
  69. Kint, J. A.Fabry's disease: alpha-galactosidase deficiency. Science 167: 1268-1269, 1970. [PubMed: 5411915] [Full Text: https://doi.org/10.1126/science.167.3922.1268\]
  70. Kirkilionis, A. J., Riddell, D. C., Spence, M. W., Fenwick, R. G.Fabry disease in a large Nova Scotia kindred: carrier detection using leucocyte alpha-galactosidase activity and an NcoI polymorphism detected by an alpha-galactosidase cDNA clone. J. Med. Genet. 28: 232-240, 1991. [PubMed: 1677424] [Full Text: https://doi.org/10.1136/jmg.28.4.232\]
  71. Ko, Y.-H., Kim, H.-J., Roh, Y.-S., Park, C.-K., Kwon, C.-K., Park, M.-H.Atypical Fabry's disease: an oligosymptomatic variant. Arch. Path. Lab. Med. 120: 86-89, 1996. [PubMed: 8554452]
  72. Kornreich, R., Bishop, D. F., Desnick, R. J.Alpha-galactosidase A gene rearrangements causing Fabry disease: identification of short direct repeats at breakpoints in an Alu-rich gene. J. Biol. Chem. 265: 9319-9326, 1990. [PubMed: 2160973]
  73. Koto, Y., Sakai, N., Lee, Y., Kakee, N., Matsuda, J., Tsuboi, K., Shimozawa, N., Okuyama, T., Nakamura, K., Narita, A., kobayashi, H., Uehara, R., Nakamura, Y., Kato, K., Eto, Y.Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan. Molec. Genet. Metab. 133: 277-288, 2021. [PubMed: 34090759] [Full Text: https://doi.org/10.1016/j.ymgme.2021.05.004\]
  74. Lemansky, P., Bishop, D. F., Desnick, R. J., Hasilik, A., von Figura, K.Synthesis and processing of alpha-galactosidase A in human fibroblasts: evidence for different mutations in Fabry disease. J. Biol. Chem. 262: 2062-2065, 1987. [PubMed: 3029062]
  75. Loonen, M. C. B., van de Lugt, L., Franke, C. L.Angiokeratoma corporis diffusum and lysosomal enzyme deficiency. (Letter) Lancet 304: 785 only, 1974. Note: Originally Volume 2. [PubMed: 4143049] [Full Text: https://doi.org/10.1016/s0140-6736(74)90984-2\]
  76. MacDermot, K. D., Holmes, A., Miners, A. H.Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. (Letter) J. Med. Genet. 38: 769-807, 2001. [PubMed: 11732485] [Full Text: https://doi.org/10.1136/jmg.38.11.769\]
  77. MacDermot, K. D., Holmes, A., Miners, A. H.Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet. 38: 750-760, 2001. [PubMed: 11694547] [Full Text: https://doi.org/10.1136/jmg.38.11.750\]
  78. MacDermot, K. D., Morgan, S. H., Cheshire, J. K., Wilson, T. M.Anderson Fabry disease, a close linkage with highly polymorphic DNA markers DXS17, DXS87, and DXS88. Hum. Genet. 77: 263-266, 1987. [PubMed: 2890570] [Full Text: https://doi.org/10.1007/BF00284482\]
  79. Maisey, D. N., Cosh, J. A.Basilar artery aneurysm and Anderson-Fabry disease. J. Neurol. Neurosurg. Psychiat. 43: 85-87, 1980. [PubMed: 6766499] [Full Text: https://doi.org/10.1136/jnnp.43.1.85\]
  80. Mapes, C. A., Anderson, R. L., Sweeley, C. C., Desnick, R. J., Krivit, W.Enzyme replacement in Fabry's disease, an inborn error of metabolism. Science 169: 987-989, 1970. [PubMed: 4914726] [Full Text: https://doi.org/10.1126/science.169.3949.987\]
  81. Mastropasqua, L., Nubile, M., Lanzini, M., Carpineto, P., Toto, L., Ciancaglini, M.Corneal and conjunctival manifestations in Fabry disease: in vivo confocal microscopy study. Am. J. Ophthal. 141: 709-718, 2006. [PubMed: 16564807] [Full Text: https://doi.org/10.1016/j.ajo.2005.11.053\]
  82. Mehta, A., Clarke, J. T. R., Giugliani, R., Elliott, P., Linhart, A., Beck, M., Sunder-Plassmann, G.Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J. Med. Genet. 46: 548-552, 2009. [PubMed: 19473999] [Full Text: https://doi.org/10.1136/jmg.2008.065904\]
  83. Moore, D. F., Kaneski, C. R., Askari, H., Schiffmann, R.The cerebral vasculopathy of Fabry disease. J. Neurol. Sci. 257: 258-263, 2007. [PubMed: 17362993] [Full Text: https://doi.org/10.1016/j.jns.2007.01.053\]
  84. Moser, H. W.Personal Communication. Baltimore, Md. 12/14/1983.
  85. Mutoh, T., Senda, Y., Sugimura, K., Koike, Y., Matsuoka, Y., Sobue, I., Takahashi, A., Naoi, M.Severe orthostatic hypotension in a female carrier of Fabry's disease. Arch. Neurol. 45: 468-472, 1988. [PubMed: 3128256] [Full Text: https://doi.org/10.1001/archneur.1988.00520280122030\]
  86. Nagao, Y., Nakashima, H., Fukuhara, Y., Shimmoto, M., Oshima, A., Ikari, Y., Mori, Y., Sakuraba, H., Suzuki, Y.Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A. Clin. Genet. 39: 233-237, 1991. [PubMed: 1645238] [Full Text: https://doi.org/10.1111/j.1399-0004.1991.tb03018.x\]
  87. Nakao, S., Kodama, C., Takenaka, T., Tanaka, A., Yasumoto, Y., Yoshida, A., Kanzaki, T., Enriquez, A. L. D., Eng, C. M., Tanaka, H., Tei, C., Desnick, R. J.Fabry disease: detection of undiagnosed hemodialysis patients and identification of a 'renal variant' phenotype. Kidney Int. 64: 801-807, 2003. [PubMed: 12911529] [Full Text: https://doi.org/10.1046/j.1523-1755.2003.00160.x\]
  88. Nakao, S., Takenaka, T., Maeda, M., Kodama, C., Tanaka, A., Tahara, M., Yoshida, A., Kuriyama, M., Hayashibe, H., Sakuraba, H., Tanaka, H.An atypical variant of Fabry's disease in men with left ventricular hypertrophy. New Eng. J. Med. 333: 288-293, 1995. [PubMed: 7596372] [Full Text: https://doi.org/10.1056/NEJM199508033330504\]
  89. Nance, C. S., Klein, C. J., Banikazemi, M., Dikman, S. H., Phelps, R. G., McArthur, J. C., Rodriguez, M., Desnick, R. J.Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch. Neurol. 63: 453-457, 2006. [PubMed: 16533976] [Full Text: https://doi.org/10.1001/archneur.63.3.453\]
  90. Novo, F. J., Kruszewski, A., MacDermot, K. D., Goldspink, G., Gorecki, D. C.Editing of human alpha-galactosidase RNA resulting in a pyrimidine to purine conversion. Nucleic Acids Res. 23: 2636-2640, 1995. [PubMed: 7503918] [Full Text: https://doi.org/10.1093/nar/23.14.2636\]
  91. Ogawa, K., Sugamata, K., Funamoto, N., Abe, T., Sato, T., Nagashima, K., Ohkawa, S.Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease. Hum. Path. 21: 1067-1073, 1990. [PubMed: 2120125] [Full Text: https://doi.org/10.1016/0046-8177(90)90258-7\]
  92. Ohshima, T., Murray, G. J., Swaim, W. D., Longenecker, G., Quirk, J. M., Cardarelli, C. O., Sugimoto, Y., Pastan, I., Gottesman, M. M., Brady, R. O., Kulkarni, A. B.Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc. Nat. Acad. Sci. 94: 2540-2544, 1997. [PubMed: 9122231] [Full Text: https://doi.org/10.1073/pnas.94.6.2540\]
  93. Ohshima, T., Schiffmann, R., Murray, G. J., Kopp, J., Quirk, J. M., Stahl, S., Chan, C.-C., Zerfas, P., Tao-Cheng, J.-H., Ward, J. M., Brady, R. O., Kulkarni, A. B.Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Nat. Acad. Sci. 96: 6423-6427, 1999. [PubMed: 10339603] [Full Text: https://doi.org/10.1073/pnas.96.11.6423\]
  94. Oliveira, J. P., Nowak, A., Barbey, F., Torres, M., Nunes, J. P., Teixeira-e-Costa, F., Carvalho, F., Sampaio, S., Tavares, I., Pereira, O., Soares, A. L., Carmona, C, Cardoso, M.-T., Jurca-Simina, I. E., Spada, M., Ferreira, S., Germain, D. P.Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: natural history in males. Europ. J. Med. Genet. 63: 103703, 2020. Note: Electronic Article. [PubMed: 31200018] [Full Text: https://doi.org/10.1016/j.ejmg.2019.103703\]
  95. Opitz, J. M., Stiles, F. C., Wise, D., Race, R. R., Sanger, R., Von Gemmingen, G. R., Kierland, R. R., Cross, E. G., DeGroot, W. P.The genetics of angiokeratoma corporis diffusum (Fabry's disease) and its linkage relations with the Xg locus. Am. J. Hum. Genet. 17: 325-342, 1965. [PubMed: 17948499]
  96. Pastores, G. M., Thadhani, R.Enzyme-replacement therapy for Anderson-Fabry disease. (Commentary) Lancet 358: 601-603, 2001. [PubMed: 11530143] [Full Text: https://doi.org/10.1016/S0140-6736(01)05816-0\]
  97. Patel, V., Watanabe, I., Zeman, W.Deficiency of alpha-L-fucosidase. Science 176: 426-428, 1972. [PubMed: 5026163] [Full Text: https://doi.org/10.1126/science.176.4033.426\]
  98. Peltier, A., Herbeuval, E., Baondeau, M. T., Belleville, F., Nabet, P.Pseudo-clinical Fabry's disease without alpha-galactosidase deficiency. Biomedicine 26: 194-201, 1977. [PubMed: 407951]
  99. Philippart, M., Sarlieve, L., Manacorda, A.Urinary glycolipids in Fabry's disease. Their examination in the detection of atypical variants and the pre-symptomatic state. Pediatrics 43: 201-206, 1969. [PubMed: 5763858]
  100. Pierides, A. M., Holti, G., Crombie, A. L., Roberts, D. F., Gardiner, S. E., Colling, A., Anderson, J.Study on a family with Anderson-Fabry's disease and associated familial spastic paraplegia. J. Med. Genet. 13: 455-461, 1976. [PubMed: 828204] [Full Text: https://doi.org/10.1136/jmg.13.6.455\]
  101. Pisani, A.Personal Communication. Naples, Italy 4/19/2005.
  102. Prigozy, T. I., Naidenko, O., Qasba, P., Elewaut, D., Brossay, L., Khurana, A., Natori, T., Koezuka, Y., Kulkarni, A., Kronenberg, M.Glycolipid antigen processing for presentation by CD1d molecules. Science 291: 664-667, 2001. [PubMed: 11158680] [Full Text: https://doi.org/10.1126/science.291.5504.664\]
  103. Pruss, H., Bohner, G., Zschenderlein, R.Paroxysmal vertigo as the presenting symptom of Fabry disease. Neurology 66: 249 only, 2006. [PubMed: 16434665] [Full Text: https://doi.org/10.1212/01.wnl.0000195280.30895.21\]
  104. Pyeritz, R. E., Ullman, M. D., Moser, A. B., Braine, H. G., Moser, H. W.Plasma exchange removes glycosphingolipid in Fabry disease. Am. J. Med. Genet. 7: 301-308, 1980. [PubMed: 6781344] [Full Text: https://doi.org/10.1002/ajmg.1320070308\]
  105. Qin, G., Takenaka, T., Telsch, K., Kelley, L., Howard, T., Levade, T., Deans, R., Howard, B. H., Malech, H. L., Brady, R. O., Medin, J. A.Preselective gene therapy for Fabry disease. Proc. Nat. Acad. Sci. 98: 3428-3433, 2001. [PubMed: 11248095] [Full Text: https://doi.org/10.1073/pnas.061020598\]
  106. Rahman, A. N., Simeone, F. A., Hackel, D. B., Hall, P. W., III, Hirsch, E. Z., Harris, J. W.Angiokeratoma corporis diffusum universale (hereditary dystopic lipidosis). Trans. Assoc. Am. Phys. 74: 366-377, 1961. [PubMed: 14489903]
  107. Rodriguez, F. H., Jr., Hoffmann, E. O., Ordinario, A. T., Baliga, M.Fabry's disease in a heterozygous woman. Arch. Path. Lab. Med. 109: 89-91, 1985. [PubMed: 2982342]
  108. Rolfs, A., Bottcher, T., Zschiesche, M., Morris, P., Winchester, B., Bauer, P., Walter, U., Mix, E., Lohr, M., Harzer, K., Strauss, U., Pahnke, J., Grossmann, A., Benecke, R.Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366: 1794-1796, 2005. Note: Erratum: Lancet 368: 2210 only, 2006. [PubMed: 16298216] [Full Text: https://doi.org/10.1016/S0140-6736(05)67635-0\]
  109. Romeo, G., Childs, B., Migeon, B. R.Genetic heterogeneity of alpha-galactosidase in Fabry's disease. FEBS Lett. 27: 161-166, 1972. [PubMed: 11946830] [Full Text: https://doi.org/10.1016/0014-5793(72)80432-0\]
  110. Romeo, G., Migeon, B. R.Genetic inactivation of the alpha-galactosidase locus in carriers of Fabry's disease. Science 170: 180-181, 1970. [PubMed: 5466114] [Full Text: https://doi.org/10.1126/science.170.3954.180\]
  111. Ropers, H.-H., Wienker, T., Grimm, T., Schroetter, K., Bender, K.Evidence for preferential X-chromosome inactivation in a family with Fabry's disease. Am. J. Hum. Genet. 29: 361-370, 1977. [PubMed: 406783]
  112. Rosenberg, D. M., Ferrans, V. J., Fulmer, J. D., Line, B. R., Barranger, J. A., Brady, R. O., Crystal, R. G.Chronic airflow obstruction in Fabry's disease. Am. J. Med. 68: 898-905, 1980. [PubMed: 6247911] [Full Text: https://doi.org/10.1016/0002-9343(80)90224-7\]
  113. Roudebush, C. P., Foerster, J. M., Bing, O. H. L.The abbreviated PR interval of Fabry's disease. New Eng. J. Med. 289: 357-358, 1973. [PubMed: 4268777] [Full Text: https://doi.org/10.1056/NEJM197308162890709\]
  114. Sakuraba, H., Yanagawa, Y., Igarashi, T., Suzuki, Y., Suzuki, T., Watanabe, K., Ieki, K., Shimoda, K., Yamanaka, T.Cardiovascular manifestations in Fabry's disease: a high incidence of mitral valve prolapse in hemizygotes and heterozygotes. Clin. Genet. 29: 276-283, 1986. [PubMed: 3087663]
  115. Sawada, K., Mizoguchi, K., Hishida, A., Kaneko, E., Koide, Y., Nishimura, K., Kimura, M.Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy. Clin. Nephrol. 45: 289-294, 1996. [PubMed: 8738659]
  116. Schiffmann, R., Kopp, J. B., Austin, H. A., III, Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., Brady, R. O.Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-2749, 2001. [PubMed: 11386930] [Full Text: https://doi.org/10.1001/jama.285.21.2743\]
  117. Schiffmann, R., Murray, G. J., Treco, D., Daniel, P., Sellos-Moura, M., Myers, M., Quirk, J. M., Zirzow, G. C., Borowski, M., Loveday, K., Anderson, T., Gillespie, F., Oliver, K. L., Jeffries, N. O., Doo, E., Liang, T. J., Kreps, C., Gunter, K., Frei, K., Crutchfield, K., Selden, R. F., Brady, R. O.Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Nat. Acad. Sci. 97: 365-370, 2000. [PubMed: 10618424] [Full Text: https://doi.org/10.1073/pnas.97.1.365\]
  118. Schiffmann, R., Ries, M., Blankenship, D., Nicholls, K., Mehta, A., Clarke, J. T. R., Steiner, R. D., Beck, M., Barshop, B. A., Rhead, W., West, M., Martin, R., Amato, D., Nair, N., Huertas, P.Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. Genet. Med. 15: 983-989, 2013. [PubMed: 23680766] [Full Text: https://doi.org/10.1038/gim.2013.56\]
  119. Schiffmann, R.Fabry disease. Pharm. Ther. 122: 65-77, 2009. [PubMed: 19318041] [Full Text: https://doi.org/10.1016/j.pharmthera.2009.01.003\]
  120. Senechal, M., Germain, D. P.Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin. Genet. 63: 46-52, 2003. [PubMed: 12519371] [Full Text: https://doi.org/10.1034/j.1399-0004.2003.630107.x\]
  121. Sheth, K. J., Good, T. A., Murphy, J. V.Heterozygote detection in Fabry disease utilizing multiple enzyme activities. Am. J. Med. Genet. 10: 141-146, 1981. [PubMed: 6274191] [Full Text: https://doi.org/10.1002/ajmg.1320100207\]
  122. Sorensen, S. A., Hasholt, L.Alpha-galactosidase isozymes in normal individuals, and in Fabry homozygotes and heterozygotes. Ann. Hum. Genet. 43: 313-321, 1980. [PubMed: 6772088] [Full Text: https://doi.org/10.1111/j.1469-1809.1980.tb01565.x\]
  123. Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., Ponzone, A., Desnick, R. J.High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. 79: 31-40, 2006. [PubMed: 16773563] [Full Text: https://doi.org/10.1086/504601\]
  124. Spada, M., Pagliardini, S.Screening for Fabry disease in end-stage nephropathies. (Abstract) J. Inherit. Metab. Dis. 25 (Suppl. 1): 113 only, 2002.
  125. Spence, M. W., Clarke, J. T. R., D'Entremont, D. M., Sapp, G. A., Smith, E. R., Goldbloom, A. L., Davar, G.Angiokeratoma corporis diffusum (Anderson-Fabry disease) in a single family in Nova Scotia. J. Med. Genet. 15: 428-434, 1978. [PubMed: 218016] [Full Text: https://doi.org/10.1136/jmg.15.6.428\]
  126. Spence, M. W., MacKinnon, K. E., Burgess, J. K., d'Entremont, D. M., Belitsky, P., Lannon, S. G., MacDonald, A. S.Failure to correct the metabolic defect by renal allotransplantation in Fabry's disease. Ann. Intern. Med. 84: 13-16, 1976. [PubMed: 812404] [Full Text: https://doi.org/10.7326/0003-4819-84-1-13\]
  127. Spinelli, L., Pisani, A., Sabbatini, M., Petretta, M., Andreucci, M. V., Procaccini, D., Lo Surdo, N., Federico, S., Cianciaruso, B.Enzyme replacement therapy with agalsidase beta improves cardiac performance in Fabry's disease. Clin. Genet. 66: 158-165, 2004. [PubMed: 15253767] [Full Text: https://doi.org/10.1111/j.1399-0004.2004.00284.x\]
  128. Stark, W. J.Personal Communication. Baltimore, Md. 11/16/1999.
  129. Sweeley, C. C., Klionsky, B.Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J. Biol. Chem. 238: 3148-3150, 1963. [PubMed: 14081947]
  130. Tagliavini, F., Pietrini, V., Gemignani, F., Lechi, A., Pallini, R., Federico, A.Anderson-Fabry's disease: neuropathological and neurochemical investigation. Acta Neuropath. 56: 93-98, 1982. [PubMed: 6278815] [Full Text: https://doi.org/10.1007/BF00690579\]
  131. Tajima, Y., Kawashima, I., Tsukimura, T., Sugawara, K., Kuroda, M., Suzuki, T., Togawa, T., Chiba, Y., Jigami, Y., Ohno, K., Fukushige, T., Kanekura, T., Itoh, K., Ohashi, T., Sakuraba, H.Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 85: 569-580, 2009. [PubMed: 19853240] [Full Text: https://doi.org/10.1016/j.ajhg.2009.09.016\]
  132. Takahashi, H., Hirai, Y., Migita, M., Seino, Y., Fukuda, Y., Sakuraba, H., Kase, R., Kobayashi, T., Hashimoto, Y., Shimada, T.Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc. Nat. Acad. Sci. 99: 13777-13782, 2002. [PubMed: 12370426] [Full Text: https://doi.org/10.1073/pnas.222221899\]
  133. Takenaka, T., Murray, G. J., Qin, G., Quirk, J. M., Ohshima, T., Qasba, P., Clark, K., Kulkarni, A. B., Brady, R. O., Medin, J. A.Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc. Nat. Acad. Sci. 97: 7515-7520, 2000. [PubMed: 10840053] [Full Text: https://doi.org/10.1073/pnas.120177997\]
  134. Testai, F. D., Gorelick, P. B.Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Arch. Neurol. 67: 19-24, 2010. [PubMed: 20065125] [Full Text: https://doi.org/10.1001/archneurol.2009.309\]
  135. Verovnik, F., Benko, D., Vujkovac, B., Linthorst, G. E.Remarkable variability in renal disease in a large Slovenian family with Fabry disease. Europ. J. Hum. Genet. 12: 678-681, 2004. [PubMed: 15162124] [Full Text: https://doi.org/10.1038/sj.ejhg.5201184\]
  136. von Scheidt, W., Eng, C. M., Fitzmaurice, T. F., Erdmann, E., Hubner, G., Olsen, E. G. J., Christomanou, H., Kandolf, R., Bishop, D. F., Desnick, R. J.An atypical variant of Fabry's disease with manifestations confined to the myocardium. New Eng. J. Med. 324: 395-399, 1991. [PubMed: 1846223] [Full Text: https://doi.org/10.1056/NEJM199102073240607\]
  137. Waldek, S., Patel, M. R., Bankiazemi, M., Lemay, R., Lee, P.Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet. Med. 11: 790-796, 2009. [PubMed: 19745746] [Full Text: https://doi.org/10.1097/GIM.0b013e3181bb05bb\]
  138. Waldek, S.PR interval and the response to enzyme-replacement therapy for Fabry's disease. (Letter) New Eng. J. Med. 348: 1186-1187, 2003. [PubMed: 12646684] [Full Text: https://doi.org/10.1056/NEJM200303203481224\]
  139. Wang, R. Y., Bodamer, O. A., Watson, M. S., Wilcox, W. R.Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet. Med. 13: 457-484, 2011. [PubMed: 21502868] [Full Text: https://doi.org/10.1097/GIM.0b013e318211a7e1\]
  140. Wang, R. Y., Lelis, A., Mirocha, J., Wilcox, W. R.Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med. 9: 34-45, 2007. [PubMed: 17224688] [Full Text: https://doi.org/10.1097/gim.0b013e31802d8321\]
  141. Wanner, C., Arad, M., Baron, R., Burlina, A., Elliott, P. M., Feldt-Rasmussen, U., Fomin, V. V., Germain, D. P., Hughes, D. A., Jovanovic, A., Kantola, I., Linhart, A., and 13 others.European expert consensus statement on therapeutic goals in Fabry disease. Molec. Genet. Metab. 124: 189-203, 2018. [PubMed: 30017653] [Full Text: https://doi.org/10.1016/j.ymgme.2018.06.004\]
  142. Whybra, C., Kampmann, C., Willers, I., Davies, J., Winchester, B., Kriegsmann, J., Bruhl, K., Gal, A., Bunge, S., Beck, M.Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J. Inherit. Metab. Dis. 24: 715-724, 2001. [PubMed: 11804208] [Full Text: https://doi.org/10.1023/a:1012993305223\]
  143. Wilcox, W. R., Banikazemi, M., Guffon, N., Waldek, S., Lee, P., Linthorst, G. E., Desnick, R. J., Germain, D. P.Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75: 65-74, 2004. [PubMed: 15154115] [Full Text: https://doi.org/10.1086/422366\]
  144. Wise, D., Wallace, H. J., Jellinek, E. H.Angiokeratoma corporis diffusum: a clinical study of eight affected families. Quart. J. Med. 31: 177-206, 1962. [PubMed: 14007664]